Literature DB >> 32389118

COX and PTGDS Gene Expression Levels in PGD2 Synthesis Pathway are correlated with miR-520 in Patients with Vessel Restenosis.

Shima Rezaee1, Naser Kakavandi1, Mohammad Shabani1, Mohsen Khosravi2, Seyed R Hosseini-Fard3, Mohammad Najafi1.   

Abstract

BACKGROUND: The vessel restenosis is related to the inflammatory events in subendothelial space. It is proposed that the inflammatory agents affect the prostaglandin synthesis pathway. In this study, we investigated the COX-1, COX-2, PTGDS and miRNA-520a-5p expression levels and the serum 15-Deoxy-∆ 12,14 -PGJ2 metabolite values in patients with the stenosed and re-stenosed vessels. Furthermore, the associations between genes and miR-520 were evaluated in the monocyte transfection studies.
METHODS: The subjects (n=60) were included three groups; healthy subjects (control (stenosis < 5%), stent no restenosis (SNR, restenosis < 5%) and in-stent restenosis (ISR, restenosis > 70%)). The miRNA and gene expression levels were measured by RT-qPCR technique. 15-Deoxy-∆ 12,14 -PGJ2 values were measured by the ELISA technique. The miR-520 was transfected into myocytes using PEI polymer.
RESULTS: The monocyte COX-1, COX-2 and PTGDS gene expression levels and the serum 15- Deoxy-∆ 12,14 -PGJ2 values increased significantly in the patients. Furthermore, the miR-520 correlated conversely with the COX-1, and PTGDS gene expression levels.
CONCLUSION: The results showed that the PGD2 synthesis pathway is active in the patients and, miR-520 may be involved in the function of this pathway. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  COX-1; COX-2; PGD2; PTGDS.zzm321990; Restenosis; Stenosis; miR-520a-5p

Year:  2020        PMID: 32389118     DOI: 10.2174/1871530320666200511012142

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  3 in total

1.  Multi-omics study of silicosis reveals the potential therapeutic targets PGD2 and TXA2.

Authors:  Junling Pang; Xianmei Qi; Ya Luo; Xiaona Li; Ting Shu; Baicun Li; Meiyue Song; Ying Liu; Dong Wei; Jingyu Chen; Jing Wang; Chen Wang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

2.  Lipid metabolism patterns and relevant clinical and molecular features of coronary artery disease patients: an integrated bioinformatic analysis.

Authors:  Yanhui Liao; Zhenzhen Dong; Hanhui Liao; Yang Chen; Longlong Hu; Zuozhong Yu; Yi Xia; Yuanbin Zhao; Kunpeng Fan; Jingwen Ding; Xiongda Yao; Tianhua Deng; Renqiang Yang
Journal:  Lipids Health Dis       Date:  2022-09-10       Impact factor: 4.315

3.  Transcriptome analysis of childhood Guillain-Barré syndrome associated with supportive care.

Authors:  Ke Hu; Wanli Liu; Yi Gan; Zhaoxuan Huang
Journal:  Front Pediatr       Date:  2022-09-26       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.